Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study
Medicina · 15.04.2026 · 62 (4) · 763
DOI: 10.3390/medicina62040763 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Medicina, online erschienen am 15.04.2026. Verfasst von Fatih Yıldız und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, Turkey. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Antibodies, Monoclonal, Humanized, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Neoadjuvant systemic therapy incorporating dual HER2 blockade has significantly improved outcomes in patients with HER2-positive breast cancer. Pathological complete response (pCR) is an important surrogate endpoint associated with improved long-term survival. However, substantial heterogeneity in treatment response persists, and identifying factors associated with pCR remains clinically relevant. In addition to established clinicopathological variables, systemic inflammation-based biomarkers have recently been investigated as potential predictors of treatment response. Materials and Methods: In this multicenter retrospective study, we evaluated patients with stage II–III HER2-positive breast cancer who received pertuzumab-based neoadjuvant therapy followed by surgery between January 2023 and June 2025 across six oncology centers in Türkiye. Clinicopathological characteristics, treatment-related variables, and baseline systemic inflammation-based biomarkers were analyzed. Logistic regression analyses were performed to identify factors associated with pCR.
Results
A total of 372 patients were included, and the overall pCR rate was 61%. Higher pCR rates were observed in patients with hormone receptor-negative tumors (71.4% vs. 54.3%, p = 0.001) and in premenopausal patients (68.7% vs. 53.4%, p = 0.003). In multivariate analysis, hormone receptor status (OR 2.25, 95% CI 1.41–3.60, p < 0.001), menopausal status (OR 1.90, 95% CI 1.22–2.94, p = 0.005), neoadjuvant treatment regimen (OR 2.15, 95% CI 1.05–4.41, p = 0.037), and perineural invasion (OR 2.61, 95% CI 1.10–6.22, p = 0.030) were independently associated with pCR. In contrast, systemic inflammation-based biomarkers did not demonstrate significant associations with pCR, and ROC analyses showed limited discriminatory ability (AUC values approximately 0.5).
Conclusions
In patients with HER2-positive breast cancer treated with pertuzumab-based neoadjuvant therapy, treatment response appears to be primarily influenced by clinicopathological and treatment-related factors rather than systemic inflammatory status. Peripheral blood inflammatory biomarkers derived from routine laboratory parameters showed limited value in predicting pCR in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, Turkey.
- Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.
- Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara 06050, Turkey.
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara 06560, Turkey.
- Department of Internal Medicine, Division of Medical Oncology, Gazi Yaşargil Training and Research Hospital, Diyarbakir 21070, Turkey.
- Medical Oncology, Yüksek İhtisas University Affiliated Medicalpark Ankara Batıkent Hospital, Ankara 06370, Turkey.
ORCID-Profile: Berkan Karabuga, Salih Karatlı, İlknur Deliktas Onur, Aysegül Ilhan Gülesen, Ozgen Ahmet Yildirim, Fatih Gurler, Hatime Arzu Yasar, Ferit Aslan
Zitieren
APA
Yıldız, F., Karabuga, B., Karatlı, S., Yalınkılıç, M., Deliktas Onur, İ., Bilgic Koylu, E., Soylu Kocoğlu, S., Eraslan, E., Ilhan Gülesen, A., Erdur, E., Yildirim, O. A., Gurler, F., Yasar, H. A., & Aslan, F. (2026). Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study. Medicina, 62(4), 763. https://doi.org/10.3390/medicina62040763
Vancouver
Yıldız F, Karabuga B, Karatlı S, Yalınkılıç M, Deliktas Onur İ, Bilgic Koylu E, et al. Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study. Medicina. 2026;62(4):763. doi:10.3390/medicina62040763
BibTeX
@article{Yldz2026,
author = {Yıldız, Fatih and Karabuga, Berkan and Karatlı, Salih and Yalınkılıç, Merve and Deliktas Onur, İlknur and Bilgic Koylu, Ece and Soylu Kocoğlu, Sıla and Eraslan, Emrah and Ilhan Gülesen, Aysegül and Erdur, Erkan and Yildirim, Ozgen Ahmet and Gurler, Fatih and Yasar, Hatime Arzu and Aslan, Ferit},
title = {Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study},
journal = {Medicina},
year = {2026},
volume = {62},
number = {4},
pages = {763},
doi = {10.3390/medicina62040763}
}
EUVIMED